linjc16/ctgov huggingface dataset:
The Ovarian Reserve and Laparoscopic Ovarian Drilling

Study Overview
=================
Brief Summary
-----------------
Long term assessment of ovarian reserve after more than two years of laparoscopic ovarian drilling in Polycystic Ovary Syndrome

Detailed Description
-----------------
Inclusion criteria: Goup A: Patients with polycystic ovary syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years. Goup B: Patients with polycystic ovary syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling Anti-mullerian hormone (as an indicator for ovarian reserve) will be measured for the two groups and data collected will be compared

Official Title
-----------------
Long Term Assessment of Ovarian Reserve After More Than Two Years of Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Goup A: Patients with polycystic ovary syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years. Goup B: Patients with polycystic ovary syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling Exclusion Criteria: Age <19 or > 35 years. BMI <19 or > 35 patients refusing to participate in the study. previous ovarian cystectomy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years. | |
| B<br>Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of anti-mullerian hormone after laparoscopic ovarian drilling |  | 2 years |
Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus Infection

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to evaluate knowledge and behavior of physicians regarding Hepatitis B Virus. The investigators designed a 30-item self-administered questionnaire assessing physicians' knowledge and behavior regarding chronic Hepatitis B Virus infection. These results provide data support for updating guidelines, continuing training, and even developing policies in medical insurance.

Detailed Description
-----------------
Schedule of the study: Before March 1, 2015: study design, completing questionnaire design, and all preparatory work; Before July 1, 2015: a kick-off meeting for plot study, modifying the questionnaire, and obtaining all the questionnaires; Before September 30, 2015: finishing data entry, statistical analysis, drafting the report, and issued a final report

Official Title
-----------------
Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus

Conditions
-----------------
Hepatitis B

Intervention / Treatment
-----------------
* Other: physicians


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mainly engaged in liver disease diagnosis and treatment; Diagnosis and treatment at least 10 patients with chronic Hepatitis B Virus infection per week. Exclusion Criteria: young doctors working in less than one year; physicians working in hospital of Traditional Chinese Medicine visiting doctors.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| physicians<br>physicians taking care of patients with chronic Hepatitis B Virus infection | Other: physicians<br>* physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-item self-administered questionnaire assessing physicians' knowledge and behavior regarding chronic Hepatitis B Virus infection. |  | 5 months |
Prognostic Factors of Patients Undergoing Redo Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the prognostic significance of baseline characteristics for patients undergoing redo cardiac surgery.

Detailed Description
-----------------
Redo cardiac surgery is associated with an increased risk of postoperative morbidity and mortality. Patients undergoing redo cardiac surgery are becoming increasingly complex due to multiple comorbidities, adherence of mediastinal structures to the undersurface of the sternum as well as the spatial location of patent bypass grafts relative to the route of entry. Association estimates between baseline characteristics and outcomes in those cohort are imprecise. The aim of this study is to identify prognostic factors associated with redo cardiac surgery which may help physicians predict clinical outcomes and guide their treatment decision.

Official Title
-----------------
Prognostic Factors of Patients Undergoing Redo Cardiac Surgery

Conditions
-----------------
Redo Cardiac Surgery

Intervention / Treatment
-----------------
* Procedure: Redo cardiac surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing redo cardiac surgery Exclusion Criteria: Age <18 years; Patients with a DNR order or do not escalate care order.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality | Death from any cause at 28 days | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 60- and 90-day mortality | Death from any cause at 60- and 90-days | 60 days and 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Redo cardiac surgery, Outcome
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).

Detailed Description
-----------------
A combined Tdap (Tetanus, Diphteria, Acellular Pertussis) Vaccine Used as a Booster compared to Licensed Td (Tetanus and Diphteria) vaccine

Official Title
-----------------
A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)

Conditions
-----------------
Diphtheria, Tetanus, Acellular Pertussis

Intervention / Treatment
-----------------
* Biological: Combined diphtheria, tetanus, acellular pertussis vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP). Exclusion Criteria: Use of any other investigational drug or vaccine 30 days preceding study vaccination. Chronic administration of immunosuppressants. Administration of pre-school DTP vaccine within previous 5 years. Administration of Td booster within previous 10 years.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Combined diphtheria, tetanus, acellular pertussis vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of Diphtheria, Tetanus, Pertussis
Serotonin 1A Agonists and Cognition in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Detailed Description
-----------------
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.

Official Title
-----------------
Serotonin 1A Agonists and Cognition in Schizophrenia

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Intervention / Treatment
-----------------
* Drug: adjunctive treatment with buspirone
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for participation in the current research study. Subjects will be males and females between 18-65 years of age; Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder; The subjects or their legal guardian must sign the informed consent; Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months Exclusion Criteria: Subjects who are pregnant or lactating Subjects who have brain damage and/or neurological disorders Subjects who have current substance dependence Subjects unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>buspirone 15-30 mg qd | Drug: adjunctive treatment with buspirone<br>* buspirone 15-30 mg qd<br>|
| Placebo Comparator: 2<br>placebo | Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone |  | six weeks |
Response Shift in Patient Expectations and Functional Outcome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the results of elective lumbar spinal surgery as it relates to shifting patient expectations for outcome. Patients undergoing elective posterior spinal surgery for degenerative conditions of the spine at SWCHSC will be evaluated.

Official Title
-----------------
Response Shift in Patient Expectations and Functional Outcome Following Posterior Lumbar Spinal Surgery for Degenerative Spinal Disorders

Conditions
-----------------
Spinal Injuries

Intervention / Treatment
-----------------
* Behavioral: Perceived outcome by both patient and physician


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with a diagnosis of a degenerative condition of the lumbar spine undergoing posterior lumbar spinal surgery at Sunnybrook and Women's College Health Sciences Centre Patients who have had previous lumbar surgery Exclusion Criteria: Traumatic or neoplastic surgical conditions of the lumbar spine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Perceived outcome by both patient and physician|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Study of Sarcopenia and Aging Biomarkers by the Metabolomics

Study Overview
=================
Brief Summary
-----------------
With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.

Detailed Description
-----------------
Metabolomics is the emerging platform technology to address the complexity of a living system. In translational research, metabolomics approaches may enable the detection of multiple disease risk factors and interactions, disease progression, and response of patients to a particular therapy with or without side effects. Metabolomics may provide comprehensive information and improve diagnosis and prognosis which are particularly promising in human complex degenerative diseases. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.

Official Title
-----------------
The Study of Sarcopenia and Aging Biomarkers by the Metabolomics

Conditions
-----------------
Sarcopenia, Aging

Intervention / Treatment
-----------------
* Diagnostic Test: blood and urine sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: residents of the Chang Gung Health and Culture Village mostly independent and do not require nursing assistance capable of managing their daily living activities aged ≧ 60 Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: blood and urine sampling|Ten mL blood and 15mL urine are collected.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The biomarkers of the sarcopenia and aging in senior adults. | Metabolomics to explore the biomarkers of the sarcopenia and aging. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sarcopenia, Aging, Biomarkers, Metabolomics
The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients

Study Overview
=================
Brief Summary
-----------------
After hCG trigger a large amount of exogenous progesterone is used for luteal phase support in many countries until 10th week of gestation. Instead we suggest the use of two small doses of hCG after the trigger during the early luteal phase after GnRHa trigger, promoting the endogenous progesterone production from the corpora lutea (CL).

Official Title
-----------------
The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: hCG
* Drug: Progesterone and Estradiol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 20 and 40 Normal menstrual cycles: 25-34 days Oligomenorrhea/amenorrhea or polycystic syndrome (defined according to the Rotterdam criteria 2004) BMI >18 and <35 kg/m2 Exclusion Criteria: Patients with >14 follicles on day of trigger Previous hyperresponse with OHSS development Previous low response (less than 3 oocytes on a high dose of FSH stimulation) Endocrine disorders

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Agonist trigger<br>Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG) | Drug: hCG<br> <br> |
| Active Comparator: hCG<br>hCG trigger Pregnyl (hCG) and Progesterone and Estradiol | Drug: Progesterone and Estradiol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing pregnancy rate per patient |  | 10th week of gestation. |
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Study Overview
=================
Brief Summary
-----------------
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Detailed Description
-----------------
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.

Official Title
-----------------
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Conditions
-----------------
Bladder Neoplasms, Carcinoma, Transitional Cell

Intervention / Treatment
-----------------
* Drug: suramin


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required. No metastatic disease or muscle invasion. Clinically useful pretreatment bladder function required. No significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying. No active urinary tract infection. PRIOR/CONCURRENT THERAPY: At least 1 course of prior standard intravesical therapy required. At least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity. PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: ECOG 0 or 1. Hematopoietic: WBC at least 3,300; Hemoglobin at least 10 g/dL. Hepatic: Bilirubin no greater than 1.5 mg/dL; AST and ALT no greater than 2 times normal. Renal: Creatinine no greater than 1.5 mg/dL. OTHER: Medically able to undergo cystoscopy. No pregnant women.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: suramin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adult, Intravesical Chemotherapy
Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
This study prospectively evaluates the accuracy of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Official Title
-----------------
Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma

Conditions
-----------------
Hepatocellular Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients who receive hepatomy in our department Diagnose as HCC Diagnosis of HCC is confirmed by noninvasive criteria for HCC as used by the American Association for the Study of the Liver guidelines No history of previous treatments No pathological diagnosis before treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sensitivity, specificity, positive rate, negative rate